Objetivo Access to new medicines targeting unmet medical need is a challenge for both the Pharmaceutical industry and the member states of the European union. For the last decade the pharmaceutical sector has faced fundamental dilemmas:- The average cost to develop a single drug has tripled in a decade- Patent expirations have reduced revenue from blockbuster drugs- Attrition in the drug development pipeline remains high. - The rate of innovation in pharmaceutical development is low because of a focus on a restricted number of drug target classes and emphasis on developing “me-too” drugs. In this context, ENYO has developed an innovative systems biology based approach inspired by viruses to identify patentable chemistries directed at new human disease targets. The feasibility of this approach has been successfully demonstrated in 2015 with the identification of 40 largely unexplored novel human targets against influenza virus, which eventually resulted in the generation of leads ready for development as a therapeutic for influenza.Project MIMESIS aims to scale-up ENYO’s systems biology approach to discover original preclinical assets against human targets not previously considered tractable to drug development in both infectious (Influenza, HRV, RSV, TB and Zika) and non-infectious disease contexts (Oncology). It will scale-up the number of drug discovery targets and the disease scope and initiate the deployment of the approach to the pharmaceutical industry at the global scale. The MIMESIS approach will develop novel starting points for the development of new drugs in diseases with unmet clinical need. It will contribute to better access to medicines which will translate into higher pharmaceutical benefit to the patients. The approach has never been used before in the pharmaceutical industry and is transferable to any human disease. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencesbiological sciencesmicrobiologyvirologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health sciencesclinical medicineoncologybreast cancer Programa(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Tema(s) SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-2-2016-2017 Régimen de financiación SME-2 - SME instrument phase 2 Coordinador ENYO PHARMA Aportación neta de la UEn € 2 498 229,00 Dirección 321 AVENUE JEAN JAURES BATIMENT DOMILYON 69007 Lyon Francia Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Auvergne-Rhône-Alpes Rhône-Alpes Rhône Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 3 568 898,75
